Latest News - Zoetis
Top Corporates Hub
Zoetis
2 Profitable Stocks Worth Your Attention and 1 We Find Risky
22.05.2026 16:28
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
Stifel Maintains Hold on Zoetis, Lowers Price Target to $95
22.05.2026 08:46
Stifel analyst Jonathan Block maintains Zoetis (NYSE:ZTS) with a Hold and lowers the price target from $105 to $95.
Zoetis Probe Tests Guidance Credibility And Long Term Investor Confidence
21.05.2026 14:09
Zoetis (NYSE:ZTS) is facing an investigation into potential securities fraud tied to a sharp guidance cut following earlier positive comments about its outlook. The probe focuses on whether prior statements about growth prospects were misleading and if investors received a full and timely picture of the company’s expectations. This development raises fresh questions about management credibility, disclosure practices, and possible legal and regulatory consequences for Zoetis. Zoetis focuses...
Zoetis to Participate in Upcoming Investor Conferences
21.05.2026 12:30
PARSIPPANY, N.J., May 21, 2026--Zoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences.
Wondering what's happening in today's after-hours session?
20.05.2026 21:00
After the conclusion of the US market's regular session on Wednesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Zoetis Inc (NYSE:ZTS): A Dividend Growth Stock with Strong Profitability and Attractive Valuation
19.05.2026 11:30
Zoetis offers a strong dividend growth history and top profitability, with a 1.64% yield and P/E of 12.01, making it an attractive value play for income-focused investors.
Zoetis (ZTS) Valuation Reset After Q1 Earnings Miss And Guidance Cut
16.05.2026 14:12
Zoetis (ZTS) is under pressure after first quarter 2026 earnings missed analyst forecasts and management cut full year revenue and earnings guidance, highlighting softer U.S. companion animal demand and tougher competition in dermatology and pain. See our latest analysis for Zoetis. That weaker U.S. companion animal backdrop is showing up clearly in the share price, with Zoetis stock down about 38.5% on a 1 month share price basis and the 1 year total shareholder return declining roughly...
Jim Cramer Calls Zoetis a “Quality Company” Despite Recent Declines
14.05.2026 15:40
Zoetis Inc. (NYSE:ZTS) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer highlighted the stock’s declines, as he said: Zoetis, okay, here’s a classic 1999er. The uber-consistent animal health company is experiencing something that’s pretty hard to believe: an endless […]
Here is Why Zoetis (ZTS) is One of the Best NYSE Stocks According Analysts
14.05.2026 11:33
Zoetis Inc. (NYSE:ZTS) is one of the best NYSE stocks to buy according to Wall Street analysts. On May 7, Zoetis reported Q1 2026 revenue of $2.3 billion, a 3% increase on a reported basis but flat organically. Net income reached $601 million, with adjusted diluted EPS growing 9% to $1.53. CEO Kristin Peck noted […]
Major Purchase Alert: MICHAEL MCCALLISTER Invests $233K In Zoetis Stock
13.05.2026 15:02
A notable insider purchase on May 12, was reported by MICHAEL MCCALLISTER, Director at Zoetis (NYSE:ZTS), based on the most recent SEC filing. What Happened: MCCALLISTER's recent purchase of 3,000 shares of Zoetis, disclosed in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday, reflects confidence in the company's potential. The total transaction value is $233,273. At Wednesday morning, Zoetis shares are down by 1.63%, trading at $75.69. Discovering Zoetis: A Closer Loo
Explore the top gainers and losers within the S&P500 index in today's session.
11.05.2026 19:05
Stay updated with the movement of S&P500 stocks in today's session. Discover which S&P500 stocks are making waves on Monday.
Curious about which S&P500 stocks are generating unusual volume on Monday? Find out below.
11.05.2026 17:05
Let's have a look at the S&P500 stocks with an unusual volume in today's session.
Zoetis Q1 Review: Is A Darkened Outlook Cyclical Or Structural? (Rating Downgrade)
10.05.2026 08:45
Zoetis (ZTS) faces U.S. pet drug sales declines from generics as patents expire. Read more macroanalysis here.
These S&P500 stocks have an unusual volume in today's session
08.05.2026 17:05
Curious about which S&P500 stocks are generating unusual volume on Friday? Find out below.
Zoetis (ZTS) Is Down 24.1% After Cutting 2026 Guidance On Softer U.S. Pet Demand – Has The Bull Case Changed?
08.05.2026 08:17
In early May 2026, Zoetis reported first-quarter 2026 results showing sales of US$2,262 million and net income of US$601 million, with earnings per share rising year on year but missing analyst expectations and prompting a reduction in full-year revenue and earnings guidance. The results revealed a sharp contrast between stronger international and livestock performance and a weaker U.S. companion-animal business, where increased price sensitivity, fewer veterinary visits, and tougher...
Zoetis Inc. Q1 2026 Earnings Call Summary
08.05.2026 00:45
Moby summary of Zoetis Inc.'s Q1 2026 earnings call
Zoetis Inc (NYSE:ZTS) Q1 Earnings Miss as Pet Owners Tighten Spending and Competition Heats Up
07.05.2026 12:53
Zoetis Q1 earnings miss estimates as pet owners spend less and competition rises. Stock falls 13% on lowered revenue guidance of $9.68-$9.96B.
Top S&P500 movers in Thursday's pre-market session
07.05.2026 12:35
As we await the opening of the US market on Thursday, let's delve into the pre-market session and discover the S&P500 top gainers and losers shaping the early market sentiment.
Zoetis (NYSE:ZTS) Misses Q1 CY2026 Revenue Estimates, Stock Drops 13%
07.05.2026 11:47
Animal health company Zoetis (NYSE:ZTS) missed Wall Street’s revenue expectations in Q1 CY2026 as sales only rose 1.9% year on year to $2.26 billion. The company’s full-year revenue guidance of $9.82 billion at the midpoint came in 0.8% below analysts’ estimates. Its non-GAAP profit of $1.53 per share was 5.3% below analysts’ consensus estimates.